Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (14452)	12/2/2004 5:29:27 PM
From: Arthur Radley	Read Replies (2) \| Respond to of 52153

Could this be for real!!!!!!!!!!!! ++++++++++++++++++++++++++++++++++++++++++++++ Rita Medical moves on cancer trial By Ciara Linnane, CBS.MarketWatch.com Last Update: 4:14 PM ET Dec. 2, 2004 NEW YORK (CBS.MW) -- Shares of Rita Medical Systems surged as much as 67 percent Thursday, after it reported positive results for its radio-frequency ablation technology in a trial of lung cancer patients. The stock ended up 28 percent at $3.99, having earlier touched a high of $5.23. Volume of 11 million shares traded was about 85 times the issue's average full-day volume. Rita Medical's (RITA: news, chart, profile) RFA system, which uses radio-frequency energy to heat tissue to a high enough temperature to kill cells, achieved a 91 percent survival rate in a trial of patients with primary nonsmall-cell lung cancer after both 12 months and 18 months, the company said in a statement. Survival among patients with metastases to the lung stood at 88 percent after 12 months and 82 percent at 18 months. The trial results were reported by Professor Riccardo Lencioni, head of diagnostic and interventional radiology at the University of Pisa, Italy, at the Radiological Society of North America's annual meeting in Chicago. "We believe that radio-frequency ablation should be considered a viable alternate or complementary treatment for the many patients with pulmonary tumors who unfortunately can not undergo surgical resection," said Lencioni.

To: Biomaven who wrote (14452)	12/3/2004 9:23:26 AM
From: rkrw	Read Replies (2) \| Respond to of 52153

Is a pivotal trial that measures cancer risk for intrinsa (or libigel) practical? Would a (theoretical) increased cancer risk for micro testosterone doses emerge in a one year study no matter how many patients? Wasn't the WHI tens of thousands of patients and 10 years? How many years until they saw signals? I'm sure the fda will be more reasonable, so it will be interesting to see what they agree to. BTW: Some interesting comments on (in)validity of WHI trial on NPR. Control group and placebo group not well matched. Lots of interest in a redo. Panel comments on 1 excess "encounter" being weak could favor bpa if their plus three trysts holds up. Maybe those frigid republican abstinence mongers would agree +3 is a nice thing :-)

To: Biomaven who wrote (14452)	12/3/2004 10:04:23 AM
From: sjemmeri	Read Replies (3) \| Respond to of 52153

Peter (or anyone), I'm looking for opinions on NOVN (description below). They are being recommended by someone I respect and look like a good value. 400m market cap, 100m cash, current PE about 40 with potential new products next year that would significantly up earnings. >Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Noven's prescription patches are approved in over 30 countries, and a range of new patches are being developed in collaboration with Novartis Pharma AG, Shire Pharmaceuticals Group plc, Procter & Gamble Pharmaceuticals, Endo Pharmaceuticals Inc. and others. Together with Novartis Pharmaceuticals Corporation, Noven owns Novogyne Pharmaceuticals, a profitable women's health products company with 2003 sales of over $100 million. thanks steve